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Abstract
This observational study had the aim to assess the interaction between cognitive reserve (CR) and cerebrospinal ﬂuid b-amyloid1-42
(Ab1-42) in modulating brain [18F]ﬂuorodeoxyglucose positron emission tomography (FDG-PET) metabolism in patients with
moderate Alzheimer disease (AD).
Twenty-seven patients with probable AD and 25 neurological normal subjects (NNS) entered the study. All participants had an
FDG-PET scan, and AD patients also received a lumbar puncture to measure Ab1-42, 181p-tau, and Tau concentrations. Based on
years of formal education, AD patients were classiﬁed as highly educated-AD (years of formal education >5) or less educated-AD
(years of formal education <5). By using a voxel-wise approach, we ﬁrst investigated differences in the cerebral glucose uptake
between AD and NNS, then we assessed the interaction between level of education (a proxy of CR) and cerebrospinal ﬂuid
biomarkers on FDG-PET metabolism in the patient groups.
Signiﬁcantly lower glucose uptake was observed in the posterior cingulate gyrus, in the precuneus, in the inferior and medial
temporal gyrus, and in the inferior parietal lobule of AD patients compared with NNS. A signiﬁcant interaction was found between CR
and Ab1-42 values on brain metabolism in the inferior and medial temporal gyrus bilaterally.
The AD patients with higher CR level and marked signs of neuropathology showed glucose hypometabolism in regions typically
targeted by AD pathology. This ﬁnding supports the hypothesis that CR partially compensates for the effect of Ab plaques on cognitive
impairment, helps in patients’ clinical staging, and opens new possibilities for the development of nonpharmacological interventions.
Abbreviations: 181p-tau = hyperphosphorylated tau at threonine 181, Ab1-42 = b-amyloid1-42, AD = Alzheimer disease, ADL =
activities of daily living, CD = clock design, CR = cognitive reserve, CSF biomarkers = cerebrospinal ﬂuid biomarkers, CT =
computerized tomography, F = female, FAB = frontal assessment battery, FDG-PET = [18F]ﬂuorodeoxyglucose positron emission
tomography, GDS = 15-Item Geriatric Depression Scale, GU = cerebral glucose uptake, HE-AD = highly educated-AD, IADL =
instrumental ADL, LE-AD = less educated-AD, M = male, MMSE = Mini Mental State Examination, NNS = neurological normal
subjects, ROIs = regions of interest, SD = standard deviation, Tau = total tau.
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11. Introduction
Alzheimer disease (AD) is a neurodegenerative disorder that
typically features memory deﬁcits, followed by a progressive
decrease of cognitive abilities.[1] The neuropathology in AD is
characterized by a progressive accumulation of senile plaques and
neuroﬁbrillary tangles,whichare responsible for neuronaldeath.A
typical evolution of brain damage has been identiﬁed inADbrains,
with an earlier and prominent involvement of the medial temporal
lobes,[2] followed by involvement of lateral temporal, parietal, and
frontal regions.[3] A number of studies investigated the sensitivity
of speciﬁc biomarkers of AD pathology to discriminate between
disease stages, and to provide measures of prognostic value.[4,5]
Cerebral glucose uptake (GU), measured by brain [18F]ﬂuoro-
deoxyglucose positron emission tomography (FDG-PET), and
cerebrospinal ﬂuid biomarkers (CSF biomarkers) are regarded
as in vivo indicators of AD pathology. In particular, FDG-PET
detects brain metabolism associated with synaptic activity and
is considered as a proxy measure of neuronal integrity.[6,7] On
FDG-PET, AD is characterized by a speciﬁc regional pattern ofGU
reduction in the posterior cingulate and in the parieto-temporal
cortices.[8,9] AD symptoms essentially do not occur in the absence
of hypomethabolism, whose extent typically reﬂects the severity of
cognitive impairment.[7]
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used in the clinical diagnosis of AD, and include markers of
neuroﬁbrillary degeneration (ie, total tau [Tau] and hyper-
phosphorylated tau at threonine 181 [181p-tau] proteins) and
b-amyloid deposition (Ab peptides 1 to 42 [Ab1-42]). The use of
low CSF-Ab1-42 levels as a marker for AD pathology has been
validated in several studies, although variability exists in the
deﬁnition of cut-off values for normality.[10,11]
The relationship between AD pathology and cognition is
increasingly recognized to be complex, and not linear. The
concept of cognitive reserve (CR) was introduced to account for
the gap existing between the extent of brain tissue damage and
the clinical symptoms observed at individual level.[12] According
to this assumption, AD patients with higher as compared with
those with lower CR would require a more severe accumulation
of AD pathology to exhibit the same level of cognitive
impairment.[12] This is supported by evidence from PET studies,
indicating an inverse relationship between GU and years of
formal education (a proxy measure of static CR) in patients with
different forms of neurodegenerative dementia.[6,13]
There are several studies that examined the role of CR in
AD.[12,14–17] However, all these studies lack more direct indexes
of pathological load that, in AD, may be given by measures of
b-amyloid deposition. To the best of our knowledge, there are
few studies only that correlated CSF assessment of b-amyloid
with patients’ levels of CR,[18–20] whereas 2 studies used
b-amyloid PET imaging.[21,22]
The aim of this study was to examine the interaction between
CSF Ab1-42 and education (a proxy of CR
[23]) on brain FDG-PET
metabolism in patients with moderate AD.2. Materials and methods
2.1. Patients
Twenty-seven patients with probable AD according to the
National Institute of Neurological and Communicative Disorders
and Stroke and by Alzheimer’s Disease and Related Disorders
Association diagnostic criteria[24] (mean [SD] age: 71.5 [8.0]
years; F/M: 19/8; mean [SD] years of formal education: 7.3 [3.3])
were consecutively recruited from the Clinic of Nervous System
Diseases of OORR Foggia (Italy) between September 2012 and
June 2013. In all patients, alternative neurological and
psychiatric diagnoses were carefully investigated and excluded,
based on blood tests (complete blood count, liver, kidney, and
thyroid function tests, serum cobalamin and folate, syphilis
serology) and conventional magnetic resonance imaging (MRI)
(T2 and T1-weigthed images, ﬂuid-attenuated inversion recovery
[FLAIR] images; diffusion-weighted images). After recruitment,
patients underwent a detailed neuropsychological evaluation,
CSF assessment, and FDG-PET, as detailed below. Twenty-ﬁve
older neurological normal individuals (NNS) (mean [SD] age:
68.2 [7.0] years; F/M: 12/13; mean [SD] years of formal
education: 7.8 [4.5]) were selected from the database of the
Institute of Nuclear Medicine (OORR Foggia, Italy) and used as
control group for FDG-PET data analysis. All these subjects
suffered from cancer with no signs of brain involvement as
assessed by neurological and neuropsychological examination,
MRI (or postcontrast computerized tomography [CT]), and
visual assessment of FDG-PET images.
For the purposes of the principal aim of this study (interaction
between CR and AD pathology as assessed by FDG-PET and CSF
biomarkers), AD patients were divided in 2 subgroups based on2their level of formal education. They were therefore classiﬁed
in those highly educated-AD (HE-AD) and less educated-AD
(LE-AD) patients using the median years of formal education
(ie, 5 years) of the whole patient group as cut-off.
The study was approved by the Ethics Committee of OORR,
and all subjects gave written informed consent before taking part
in the study.2.2. Neuropsychological assessment
All patients underwent a neuropsychological examination,
measuring global cognitive functioning (by the Mini Mental
State Examination [MMSE]), verbal long-term memory (by the
Story Recall test), verbal and spatial short-termmemory (by Digit
Span, forward and backward and the Corsi Block Tapping Test),
visuospatial (by the Clock Design [CD]), and executive abilities
(by the Frontal Assessment Battery [FAB], Phonemic and
Semantic Fluencies), and attention (by the Attentional Matrices).
Mood disorders were assessed using the 15-item Geriatric
Depression Scale [GDS]). Activities of daily living (ADL) and
instrumental ADL (IADL) were used to evaluate patients’
functional impairments.2.3. CSF biomarkers
Lumbar puncture was performed in all recruited patients. CSF
was collected in 12-mL polypropylene tubes, and centrifuged at
2171g for 10minutes (3400rpm) within 2hours. A small amount
of CSF was used for routine analysis, including total cell count,
bacteriologic and microbiologic examinations, total protein, and
glucose levels. CSF was aliquoted in polypropylene tubes and
temporarily stored at 22°C to quantify, within 1 month after
collection, Ab1-42, 181p-tau, and Tau concentrations (Innotest
ELISA; Innogenetics, Ghent, Belgium). Table 1 summarizes the
mean (SD) values of Ab1-42, 181p-tau, and Tau for each patient
subgroup.2.4. PET scan acquisition and data processing
Subjects had to fast for approximately 12hours before FDG
injection. Before examination initiation, blood glucose levels
were always checked and had to be inferior to 140mg/dL.
Subjects were injected an activity of FDG equal to 37MBq/7kg of
their body mass, according to the following formula: activity to
be administered= [(mass of the patient/7)37]. Brain scanning
started 30minutes after intravenous (i.v.) administration of the
radiopharmaceutical tracer, using a layers Discovery PET/CT
600 system (GE Healthcare). CT temporal resolution was 0.25
seconds, whereas PET spatial resolution was 2.14mm (FWHM).
CT scans served for attenuation correction. Images were
reconstructed using a 3-dimensional ﬁltered back-projection
method, for a total examination duration of 6 to 8minutes. PET
images were reconstructed in repetitive Recon or Osem mode,
processed with 3DSSP, and evaluated by 2 independent nuclear
specialists.2.5. FDG-PET statistical analyses
Statistical analyses were performed at the Neuroimaging
Laboratory of Santa Lucia Foundation (Rome, Italy). FDG-
PET interﬁles were converted to Neuroimaging Informatics
Technology Initiative format and preprocessed according to the
PET protocol implemented in SPM8 (www.ﬁl.ion.ucl.ac.uk/spm/
Table 1
Principal demographic and clinical characteristics of groups with Alzheimer disease.
HE-AD (n=12) LE-AD (n=15) P
Mean (SD) age, y 68.6 (7.2) 73.9 (7.6) NS
∗
Sex (female\male) 8/4 10/5 NS†
Mean (SD) MMSE score 17.5 (6.2) 17.9 (4.7) NS
∗
Mean (SD) ADL score 4.3 (0.9) 3.8 (1.3) NS
Mean (SD) IADL score 3.4 (1.8) 3.8 (1.9) NS
Mean (SD) GDS score 5.25 (3.4) 7.5 (4.5) NS
Mean (SD) y of formal education 10.4 (2.5) 4.7 (0.7) <0.001
∗
Mean (SD) of Ab1-42 values, pg/mL 465.8 (140) 534.8 (183.6) NS
∗
Mean (SD) of 181p-tau values, pg/mL 93.3 (65.6) 62.7 (39.8) NS
∗
Mean (SD) of Tau values, ng/mL 694.9 (570) 616.3 (461.7) NS
∗
Ab1-42 values=beta-amyloid1-42 values, ADL= activities of daily living, GDS=15-Item Geriatric Depression Scale, HE-AD=highly educated Alzheimer disease, IADL= instrumental ADL, LE-AD= less educated
Alzheimer disease, MMSE=Mini-Mental State Examination, NS=not signiﬁcant, SD= standard deviation.
∗
Two-sample t test.
† Chi-square test; statistical threshold (P<0.05).
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using a 12-mm FWHM Gaussian kernel. Differences in regional
GU uptake were ﬁrst investigated between all AD patients against
NNS using a 2-sample t test design. Then, interactions between
education levels and each CSF biomarker (ie, Ab1-42, 181p-tau,
and Tau) on FDG-PET metabolism were investigated in AD
patients only. Patients were grouped in HE-AD and LE-AD, and
individual concentrations of each CSF biomarker were entered
in the design matrix as covariate of interest. Statistical tests
were all performed considering the whole brain, and results were
considered as statistically signiﬁcant for P values Family-Wise
Error cluster-level corrected <0.05. Each set of clusters resulted
as statistically signiﬁcant were used as regions of interest (ROIs)
to extract, in FSL (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/), GU
values at a single-subject level. These values were used to plot
results in as measures proportional to GU.3. Results
3.1. Demographic, clinical, and cognitive characteristics
of patients subgroups
When comparing AD patients with NNS, there were no
signiﬁcant differences in age, sex, and years of formal education.
No subject was bilingual. When comparing HE-AD with LE-AD
patients, there were no signiﬁcant differences in demographic
features, MMSE, GDS, ADL, and IADL scores, and CSFFigure 1. Pattern of GU between AD and NNS. Panel A shows regions of signiﬁcant
bilateral posterior cingulate, precuneus, and lateral parieto-occipital cortices. Panel B s
in the right parieto-occipital cortex.AreasofGUare shown in redandoverlaidonto aT1
AD=Alzheimer disease, FEW=Family-Wise Error, GU=glucose uptake, L= left, NN
3biomarkers (Table 1). Additionally, there were no signiﬁcant
differences in the cognitive functions betweenHE-AD and LE-AD
patients.3.2. Conventional brain MRI
Conventional brain MRI images were examined by an expert
radiologist, who conﬁrmed the expected pattern of brain atrophy
in all AD patients (irrespective of individual CR level), which was
dominated by a bilateral tempore-parietal distribution.3.3. FDG-PET
Between-group comparison revealed signiﬁcant clusters of low
GU in AD compared with NNS in the posterior cingulate gyrus
and precuneus, in the inferior and medial temporal gyrus, and in
the inferior parietal lobe bilaterally (Fig. 1 and Supplemental
Table 2, http://links.lww.com/MD/B624).
In AD patients, the interaction between CR and CSF-
biomarkers on FDG-PET metabolism returned signiﬁcant results
when considering b-amyloid levels only. Selective modulation of
CR on brain metabolism was found in the inferior and medial
temporal gyrus bilaterally (Supplemental Table 3, http://links.
lww.com/MD/B624). Such an interaction was driven by a
negative association between CSF b-amyloid levels (inversely
correlated to amyloid plaque deposition) and GU in HE-AD
patients, and a direct association in LE-AD patients (Fig. 2).difference (FWE, P<0.05 at cluster level) in values of GU between AD and NNS in
hows the plot of between-groups signiﬁcant differences (
∗
P=0.003) inGU located
-weighted template.MNI coordinates are reported for eachsection.Abbreviations:
S=neurological normal subjects, R= right (see text for further details).
Figure 2. Interaction between education and Ab1-42 values in 2 patient groups. Panel A shows regional changes in GU between AD divided in those with a higher
(HE-AD) and those with a lower educational level (LE-AD) in the inferior andmedial temporal gyrus (statistical threshold set to FWE, P<0.05 at cluster level). Areas of
GU are shown in red and overlaid onto a T1-weighted template. MNI coordinates are reported for each section. Panel B shows interaction between GU in the inferior
and medial temporal gyrus bilaterally and CSF Ab1-42, in which patients with higher educational level (HE-AD) showed reduced metabolism than those with lower
educational level (LE-AD). Abbreviations: AD=Alzheimer disease, CSF Aß1-42=cerebrospinal ﬂuid beta-amyloid1-42, FEW=Family-Wise Error, GU=glucose
uptake, HE-AD=highly educated-AD, L= left, LE-AD = less educated-AD, NNS=neurological normal subjects, R= right (see text for further details).
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This study investigated the impact of CR on brain metabolism in
AD, by controlling for the load of AD pathology assessed by CSF
biomarkers. We ﬁrst replicated previous ﬁndings by comparing
all AD patients (irrespective of their CR level) and healthy
controls. Consistent with previous literature,[8,9] patients with
AD reported a signiﬁcant decrease of GU in the cingulate gyrus
and precuneus and in parieto-temporal regions.
Then, we examined the interaction between CR and speciﬁc
measures of brain pathology on brain functioning. As expected
by a consecutive patient recruitment, HE-AD and LE-AD patients
were similar for demographic and clinical characteristics, and
years of disease onset. According to our analysis, b-amyloid was
the only biomarker showing an interaction between CR and
brain metabolism. This is not surprising for several reasons,
including the central role of b-amyloid accumulation in AD
pathophysiology,[25,26] and its partial dissociation from phenom-
ena of neuronal death.[27] Conversely, tau tangle formation is
known to reﬂect neuronal loss, thus being strictly associated with
cognitive impairment beyond any potential effect of CR.[28]
Themain ﬁnding of the current study is the interaction between
patients’ CR and b-amyloid deposition on metabolism in the
medial temporal lobes, which have been previously shown as
particularly sensitive to Ab1-42 level.
[29,30] In HE-AD patients,
CRwas inversely associated with GU, whereas the opposite effect
was observed in LE-AD patients. This is in line with the CR
theory and with a number of previous neuroimaging studies,
indicating a compensatory effect of CR against accumulation of
pathological damage.[14] In other words, our ﬁndings suggest
that, at least in early/moderate stages of AD, CR compensates
neurodegeneration and allows the maintenance of patients’
cognitive performance as previously argued by others.[14,31,32]
The selective anatomical distribution we found in the medial
temporal lobes of our patients is consistent with their clinical
presentation, which was in all cases amnestic. However, it has
been recently shown that AD also includes atypical variants (ie,
nonamnestic AD)[33–36] and that they are more common than it
was thought before.[33] Further studies are needed to clarify4whether the effect of CR we described here can be extended also
to patients with atypical AD. This is relevant not only for
speculative reasons on the pathophysiology of AD. Indeed, in the
absence of treatments, with the ability of modifying the natural
history of the disease, CRmight open to potential interventions to
mitigate the impact of AD. This is particularly relevant for
patients at early or even preclinical AD stages. As recently
reported by Ewers et al, CR interacts with individual b-amyloid
status on brain metabolism in the temporo-parietal lobes of
cognitively normal individuals.
Local GM volumes of these parietal association regions were
found to be less atrophic in AD patients with higher as compared
with those with lower education levels.[32]
This study suffers from some limitations, including sample size
and assessment of CR based on education only. Subjects serving
as controls (even if with no signs of brain involvement as assessed
by neurological and neuropsychological examination) suffered
from cancer.
Nevertheless, our patient sample was well-selected and
clinically homogeneous. With respect to education, this is
certainly a simplistic way for measuring CR. However, education
is one of the most widely used and reliable proxy measure of CR
in literature, thus facilitating a comparison between current
ﬁndings and previous studies.[23] In addition, it is important to
highlight that the motivation behind choosing education as a
proxy for CR is that, although occurring early in life, education
tends to inﬂuence lifestyle throughout the entire life.
In conclusion, this supported evidence for the role played by
CR theory in neurodegeneration, by assessing in vivo the severity
of AD pathology in patients at amoderate stage of disease. Due to
the experimental design, the main potential sources of sample
variability were well-controlled, thus identifying the speciﬁc
interaction between subjective level of CR and accumulation of
AD pathology. This is relevant for clinical reasons as we currently
do not have reliable prognostic measures on patient clinical
outcome to be applied at a single subject level. Understanding the
protective role of CR might improve our prognostic accuracy in
clinical practice, and also in patients’ stratiﬁcation for future
clinical trials.
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